Tesamorelin Research for Cognitive Function
An evidence-based overview of research examining Tesamorelin in the context of cognitive function. This page synthesizes findings from peer-reviewed literature.
Research Summary
The TEAME trial investigated tesamorelin for cognitive function in HIV-positive individuals with abdominal obesity, hypothesizing that visceral adiposity contributes to neuroinflammation and reduced IGF-1, impairing cognition.
Results showed a trend toward cognitive improvement (p=0.060) but did not reach statistical significance between groups. Significant reductions in waist circumference (-2.7 cm) were achieved, suggesting the intervention worked mechanistically but cognitive effects may require longer duration.
The study was underpowered and lacked a true placebo arm, leaving the cognitive hypothesis incompletely tested. Further research is needed to determine whether sustained VAT reduction translates to cognitive benefits.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Cognitive Function
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Tesamorelin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.